Get the Stockscreener App
1.06
1.92%
0.02
After Hours:
1.06
Neurosense Therapeutics Ltd stock is traded at $1.06, with a volume of 285.95K.
It is up +1.92% in the last 24 hours and down -14.52% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.04
Open:
$1.05
24h Volume:
285.95K
Relative Volume:
0.98
Market Cap:
$23.93M
Revenue:
-
Net Income/Loss:
$-13.76M
P/E Ratio:
-1.1398
EPS:
-0.93
Net Cash Flow:
-
1W Performance:
-6.19%
1M Performance:
-14.52%
6M Performance:
+46.98%
1Y Performance:
-1.85%
1-Day Range:
$1.01
$1.08
1-Week Range:
$1.01
$1.14
52-Week Range:
$0.512
$2.33
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.06 | 23.93M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
NeuroSense Therapeutics Reports Key Progress and Financials - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.4% – Here’s What Happened - Defense World
NeuroSense regains Nasdaq compliance with equity boost - Investing.com
NeuroSense regains Nasdaq compliance with equity boost By Investing.com - Investing.com Nigeria
NeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS Treatment - TipRanks
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - StreetInsider.com
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - GuruFocus.com
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit - GuruFocus.com
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In R - GuruFocus.com
Neurosense Therapeutics Ltd (NRSN-Q) QuotePress Release - The Globe and Mail
Analyzing NeuroSense Therapeutics (NASDAQ:NRSN) & Avidity Biosciences (NASDAQ:RNA) - Defense World
NeuroSense Partners with Pharma Giant to Propel ALS Drug PrimeC - TipRanks
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS - Nasdaq
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Shares Bought by XTX Topco Ltd - Defense World
NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position - TipRanks
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results - citybiz
NeuroSense's ALS Drug Shows Breakthrough Results: 58% Better Survival Rate in Phase 2b Trial - StockTitan
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) - Aktiellt
NeuroSense Therapeutics Regains Nasdaq Compliance - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Hold” Rating from Maxim Group - Defense World
Maxim cuts NeuroSense shares rating to hold on capital concerns By Investing.com - Investing.com South Africa
Maxim cuts NeuroSense shares rating to hold on capital concerns - Investing.com
Comparing Emmaus Life Sciences (OTCMKTS:EMMA) & NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
NeuroSense aligns with FDA on Phase 3 ALS drug study By Investing.com - Investing.com Australia
NeuroSense Receives FDA Approval for Phase 3 Study of ALS Treatment - TipRanks
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Desig - GuruFocus.com
NeuroSense aligns with FDA on Phase 3 ALS drug study - Investing.com
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC - Marketscreener.com
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC (PR Newswire) - Aktiellt
Dewpoint Therapeutics and Mitsubishi Tanabe partner on ALS therapy - European Biotechnology News
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS - The Malaysian Reserve
NeuroSense Announces Completion of PARADIGM Study Highlighting P - GuruFocus.com
NeuroSense Therapeutics Ltd. Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS - Marketscreener.com
NeuroSense’s PrimeC Shows Promise in ALS Treatment - TipRanks
NeuroSense Therapeutics Ltd. announced that it expects to receive $5 million in funding - Marketscreener.com
NeuroSense secures $5 million in private placement funds By Investing.com - Investing.com Nigeria
NeuroSense Therapeutics Announces Securities Purchase Agreement - TipRanks
NeuroSense Therapeutics Announces $5 Million Private Placement - citybiz
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price - Lelezard
NeuroSense secures $5 million in private placement funds - Investing.com India
NeuroSense Secures $5M Private Placement at 25% Premium, CEO Joins Investment - StockTitan
Exosome Diagnostics & Therapeutics Market Assessment - GlobeNewswire
NeuroSense Therapeutics Plans to File for Early Commercializatio - GuruFocus.com
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Tr - GuruFocus.com
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstr - GuruFocus.com
NeuroSense Advances Plans for Early Commercialization of Groundb - GuruFocus.com
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS, MND - Marketscreener.com
NeuroSense Therapeutics Ltd. announced that it expects to receive $30 million in funding - Marketscreener.com
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - PR Newswire
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS i - GuruFocus.com
NeuroSense Therapeutics Secures Continued Nasdaq Listing - TipRanks
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):